San Jose, California (ots/PRNewswire) - - Fully-featured Platform to Optimize External DDR2 and Flash Memory Organization for Maximum Performance and Cost-effective Data Storage Atmel(R) Corporation (Nasdaq: ATML) today announced the SAM9G45-EK evaluation kit to support application development on the company's 400 MHz ARM926(TM)-based embedded microprocessor ...
Bristol-Myers Squibb and AstraZeneca
Princeton, New Jersey and London (ots/PRNewswire) - Results from an 18-week phase 3b study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy alone found that the addition of treatment with ONGLYZA(TM) (saxagliptin) 5 mg per day achieved the primary objective of ...
Bristol-Myers Squibb and AstraZeneca
Paris and London (ots/PRNewswire) - Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) (LSE: AZN) announced today that the European Commission has granted marketing authorisation for Onglyza in the 27 countries of the European Union. Onglyza is indicated as a once-daily 5 mg oral tablet dose ...
Houston (ots/PRNewswire) - AVEVA Group plc (LSE:AVV), the leading provider of plant design and engineering lifecycle solutions, today announced that Ambitech has added AVEVA Laser Model Interface to its project execution portfolio. AVEVA Laser Model Interface combines the power of AVEVA PDMS and AVEVA Outfitting design environments with advanced third-party laser modeling systems to bring massive benefits to plant ...
Montreal, Canada (ots/PRNewswire) - Cirque du Soleil, the artistic producer of the Moving Stars and Earth for Water event, today revealed the program details for the global artistic event as part of Guy Laliberté's Poetic Social Mission. For information on the specific involvement of each of the personalities, ...
Bristol-Myers Squibb GmbH & Co. KGaA
Princeton, New Jersey (ots/PRNewswire) - New data on four Bristol-Myers Squibb Company (NYSE: BMY) compounds will be presented at the 60th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 30 to November 3. Data will be presented on BARACLUDE(R) (entecavir) in patients with chronic hepatitis B, and on ...
Takeda Pharmaceutical Company Limited
Osaka, Japan (ots/PRNewswire) - Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") announced today it will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries - Takeda Pharmaceuticals Mexico, S.A. de C.V., Takeda ...
Bethesda, Maryland (ots/PRNewswire) - American Capital Ltd. (Nasdaq: ACAS), parent company of European Capital Financial Services Ltd. ("ECFS"), today announced the closure of its Frankfurt affiliate. The closure of the Frankfurt office is in response to the global downturn in the private equity markets over the past two years. The assets originated by the ...
Abbotsford, Canada (ots/PRNewswire) - ICS Copper Systems Ltd. (ICX: TSX.V) is pleased to announce that it has arranged a non-brokered private placement of 1,000,000 (One Million) units at a price of CDN$0.10 per unit for gross proceeds of CDN$100,000. Each unit will consist of one common share and one full warrant entitling the holder to purchase a common share at a price of CDN$0.12 if exercised within a period of ...
San Jose, California (ots/PRNewswire) - Atmel(R) Corporation (Nasdaq: ATML) today announced that the BitCloud(TM) ZigBee(R) PRO stack has been awarded ZigBee Smart Energy product certification. BitCloud Smart Energy offers utility companies a secure, proven and easy-to-use technology for wireless home area networks (HANs) by connecting in-premise devices, such ...
Paris (ots/PRNewswire) - - 76% Higher Dose of Insulin detemir Needed to Achieve Similar, Well Tolerated Glycemic Control Versus Lantus(R) Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine [rDNA] injection) compared to twice-daily insulin detemir. The study was ...
Brussels (ots/PRNewswire) - - New Study Reveals Musculoskeletal Disorders (MSDS) Responsible for More Sick Days Than any Other Health Condition A new study today finds that musculoskeletal disorders (MSDs) account for nearly half (49%) of all absences from work and 60% of permanent work incapacity in the European Union. These and other socio-economic ...
Brussels (ots/PRNewswire) - - New Study Reveals Musculoskeletal Disorders (MSDS) Responsible for More Sick Days Than any Other Health Condition A new study today finds that musculoskeletal disorders (MSDs) account for nearly half (49%) of all absences from work and 60% of permanent work incapacity in the European Union. These and other socio-economic ...
Baikonur Cosmodrome, Kazakhstan (ots/PRNewswire) - - Actors Matthew McConaughey and Salma Hayek, Singers Joss Stone and Élisapie Isaac, Musical Group Ladysmith Black Mambazo, Bolshoi Ballet Principal Dancer Nicolai Tsiskaridze and Poet Touria Ikbal Join Former U.S. Vice President Al Gore, U2, and Others in ...
Calgary, Canada (ots/PRNewswire) - - Powerful Effects Seen in all Subjects Including Those With Low HDL - Representing a Majority of Myocardial Infarct Patients TSX Exchange Symbol: RVX Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that results from the Company's Phase ...
San Jose, California (ots/PRNewswire) - - ATmega1284P reduces design footprint by doubling flash and quadrupling RAM size compared to existing picoPower megaAVR microcontrollers Atmel(R) Corporation (Nasdaq: ATML) today announced the availability of a 128 KB picoPower(R) megaAVR(R) microcontroller, targeting size-constrained, low-power applications. The ...
San Jose, California (ots/PRNewswire) - - Increased functionality and integration enable designers to embed touch interface technology quickly and efficiently Atmel(R) Corporation (Nasdaq: ATML) today announced version 3.0 of the royalty-free Atmel QTouch(R) software library with up to 64 channels of touch support for all Atmel AVR microcontrollers ...
Ingelheim, Germany (ots/PRNewswire) - - For Non-US Healthcare Media Following the release of linagliptin Phase II data earlier this year, Boehringer Ingelheim has now announced the conclusion of the linagliptin pivotal Phase III clinical trials. The company confirmed that first results from the Phase III ...
Abbott Park, Illinois (ots/PRNewswire) - - Diversifies Abbott's pharmaceutical products, expanding international growth platform - Supports long-term strategy to bolster presence in key global emerging markets - Adds substantial R&D spending capacity to accelerate promising pipeline programs - Establishes Abbott's presence in the growing global vaccines market - Provides accretion of approximately ...
Calgary, Canada (ots/PRNewswire) - Resverlogix Corp. (TSX:RVX) announced today that it will host a live teleconference and webcast on Tuesday, September 29, 2009 at 1:00 pm Eastern/11:00 am Mountain time. The purpose of the teleconference is to discuss the top line results of the Company's Phase 1b/2a clinical trial for RVX-208, an oral small molecule in development ...
Paris (ots/PRNewswire) - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq(R) (dronedarone - 400mg Tablets). The CHMP has recommended the ...
Collegeville, Pennsylvania (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the company's pneumococcal conjugate vaccine, Prevenar ...
San Francisco (ots/PRNewswire) - Abbott (NYSE: ABT) today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial. PROSPECT is the first prospective natural history study to evaluate the role of vulnerable ...
Berlin (ots/PRNewswire) - Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab ...
London (ots/PRNewswire) - - With the Launch of Corby(TXT) and Corby(PRO), Samsung Quickly Strengthens its Position in the Youth Market Samsung Electronics Co. Ltd, (LSE: SMSN) a leading mobile phone provider, has rapidly followed the successful launch of the Samsung Corby (model: S3650), its first mobile handset designed to support the highly connected ...
San Francisco (ots/PRNewswire) - - Independent Study of 1,800 Patients Affirms Outstanding Performance of XIENCE V vs. TAXUS Liberte Late-breaking data presented today from the COMPARE trial demonstrated that Abbott's (NYSE: ABT) market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System ...
San Francisco (ots/PRNewswire) - At One Year, XIENCE V Demonstrates: - Statistical Superiority on Primary Endpoint of Target Lesion Failure, with a 38 Percent Reduction Compared to TAXUS - 74 Percent Reduction in Stent Thrombosis (Blood Clots) Compared to TAXUS - Low Event Rates across Multiple ...
Jena, Germany (ots/PRNewswire) - Occlutech GmbH, the leading European developer of products for septal closure, today announced that the district court of Frankfurt, Germany reversed an earlier court injunction obtained by AGA Medical against Occlutech's sales and marketing activities relating to the newly launched Figulla Flex ranges of ASD and PFO occluders. ...
Maidenhead, England (ots/PRNewswire) - - 26 Men and Women With RA From Across Europe Honoured as They Share Their Inspirational Stories Actress, artist and activist Jane Seymour will host the first My Day for RA European event in Barcelona, Spain this evening to recognise the daily challenges, hopes and ...